Price transparency in healthcare has become more important as consumers increasingly engage in healthcare decision making and are asked to pay more for their care.
Price transparency in healthcare has become more important as consumers increasingly engage in healthcare decision making and are asked to pay more for their care. A new issue brief from America’s Health Insurance Plans (AHIP) takes a look at price transparency efforts, barriers to improved price transparency, and structuring future initiatives.
Making healthcare cost information readily available and usable by consumers is one way health plans and employers are hoping to improve efficiency, clinical effectiveness, and value.
“As a result of the increased recognition of the value of price transparency in informing consumer decision-making and promoting efficient, quality care, health plans, as well as the federal and state governments, have taken steps to increase the availability of price information for health care services and promote its use in consumer decision-making,” according to the AHIP issue brief.
There are really 2 main challenges to implementing price transparency in healthcare, according to the report. One challenge to greater price transparency is that the definition of cost may change depending on who is incurring the cost: the patient, the provider, the insurer, or the employer. The second challenge is simply availability of price information and public interest in using the data provided.
The use of price transparency tools has many benefits. For instance, price transparency for a procedure can reduce that procedure’s market price.
“Price transparency can also reduce claims payments for lab tests, advanced imaging, and clinician office visits, and reduce overall payments made for clinical care,” according to the issue brief.
AHIP also provided key elements that should be used to evolve initiatives and tools to make provider price information available:
“As price transparency initiatives and tools continue to evolve, stakeholders should pursue continued emphasis on the integration of quality information, given existing evidence that cost data, presented with quality data, can influence consumer decision-making and lead to value-based choices,” the brief concludes.
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More